iXCells Biotechnologies has appointed Steve Smith chief executive officer. Previously chief commercial officer, Mr Smith will lead the provision of the company’s bespoke human-derived iPSC (induced pluripotent stem cells) preclinical services. With 25 years’ experience in the life sciences industry, he was most recently CCO at seqWell, a provider of genomic library and multiplexing workflow solutions. iXCells is focused on supporting larger, more complex preclinical programmes, and expanding multi-study collaborations with biotech, pharmaceutical, academic and CRO partners.
iXCells Biotechnologies announced the appointment on 12 January 2026.
Copyright 2026 Evernow Publishing Ltd.